BCA
IMDX

Berman Capital Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Berman Capital Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
+16
New +$1.47K ﹤0.01% 1925

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's IMDX Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2021: 16 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1925 among its holdings.

95 funds tracked by Wall St. Rank hold IMDX as of Q3 2021.

  • Berman Capital Advisors held 16 shares of Insight Molecular Diagnostics worth $1K as of Q3 2021.
  • Insight Molecular Diagnostics was a new Berman Capital Advisors position in Q3 2021.
  • Insight Molecular Diagnostics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1925 holding.
  • 95 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.